Q-omics provides the consensus-scored GFRA4 profile across patient tissues and cancer cell-line models. GFRA4 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GFRA4 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, GFRA4 RNA expression shows 6,441 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KICH, and STAD as cancer lineages where GFRA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GFRA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GFRA4 survival associations across molecular data types. GFRA4 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GFRA4 RNA expression–survival associations across cancer types. High GFRA4 expression shows unfavorable associations in UCEC, CHOL, SCLC, KIRC, BLCA and COAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for GFRA4 RNA expression.
This table summarizes GFRA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GFRA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GFRA4 shows lower tumor expression in KICH, KIRC, THCA, HNSC and KIRP and higher tumor expression in LIHC. The KICH box plot shows higher GFRA4 RNA expression in normal versus tumor tissue (log2 FC = −0.072, t-test p = .002).
This table shows molecular features associated with GFRA4 in patient tissues and cancer cell lines. In patient samples, GFRA4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GFRA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
